Key points from article :
Rejuvenate Bio partners with a leading animal health company to develop gene therapy for canine osteoarthritis (OA).
OA affects over 40% of dogs, causing pain, mobility issues, and reduced quality of life.
Existing treatments include biopharmaceuticals, but new options with different targets are needed.
“This partnership validates our technology and approach of utilizing gene therapy to treat chronic age-related diseases," - Daniel Oliver, CEO & Co-Founder of Rejuvenate Bio.
Rejuvenate Bio’s gene therapy offers a one-dose injection for long-term relief and disease modifying action.
Therapy targets the underlying causes of OA, improving joint health and quality of life.
May eventually benefit humans suffering from osteoarthritis in the future.
